NasdaqGM - Nasdaq Real Time Price USD

NeuroPace, Inc. (NPCE)

Compare
12.99
-0.55
(-4.06%)
As of 3:00:13 PM EDT. Market Open.
Loading Chart for NPCE
  • Previous Close 13.54
  • Open 13.01
  • Bid 12.91 x 100
  • Ask 13.15 x 300
  • Day's Range 12.11 - 13.04
  • 52 Week Range 5.45 - 15.77
  • Volume 174,132
  • Avg. Volume 242,363
  • Market Cap (intraday) 422.956M
  • Beta (5Y Monthly) 2.04
  • PE Ratio (TTM) --
  • EPS (TTM) -0.93
  • Earnings Date May 6, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 17.57

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides Physician Tablet, Patient Data Management System, and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

www.neuropace.com

184

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NPCE

View More

Performance Overview: NPCE

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NPCE
16.09%
S&P 500 (^GSPC)
7.61%

1-Year Return

NPCE
5.01%
S&P 500 (^GSPC)
4.27%

3-Year Return

NPCE
53.18%
S&P 500 (^GSPC)
19.54%

5-Year Return

NPCE
44.13%
S&P 500 (^GSPC)
118.36%

Compare To: NPCE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NPCE

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    440.86M

  • Enterprise Value

    461.45M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.94

  • Price/Book (mrq)

    55.02

  • Enterprise Value/Revenue

    5.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -33.97%

  • Return on Assets (ttm)

    -13.39%

  • Return on Equity (ttm)

    -189.35%

  • Revenue (ttm)

    79.91M

  • Net Income Avi to Common (ttm)

    -27.14M

  • Diluted EPS (ttm)

    -0.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    52.76M

  • Total Debt/Equity (mrq)

    915.24%

  • Levered Free Cash Flow (ttm)

    -10.7M

Research Analysis: NPCE

View More

Company Insights: NPCE

Research Reports: NPCE

View More

People Also Watch